Literature DB >> 21437595

PSA density versus risk stratification for lymphadenectomy-making decision in patients with prostate cancer undergoing radical prostatectomy.

Stavros Sfoungaristos1, Petros Perimenis.   

Abstract

OBJECTIVES: To determine the value of PSA density as independent predictor for lymph node invasion in order to decide lymphadenectomy in patients undergoing radical prostatectomy. PATIENTS AND METHODS: We retrospectively analyzed the medical records of 179 patients who undergone radical prostatectomy from January 2001 until September 2010. Studied patients divided in groups regarding the preoperative risk for lymph node metastasis (low risk or not) and PSA density (≤.2 or greater). Age, prostate volume, preoperative PSA, and preoperative Gleason score (≤ 6 or ≥ 7) were estimated as well. We analyze the impact of the above factors in prediction of lymph nodes metastasis after radical prostatectomy.
RESULTS: One patient found to have lymph node invasion out of 48 who stratified as low-risk patients and 1 out of 77 who had PSA density ≤.2. There was a significant correlation between preoperative PSA, PSA density, and risk stratification among patients who had metastasis or not. These findings confirmed in the univariate analysis of these factors. However, in multivariate analysis, PSA density was the only statistically significant predictor.
CONCLUSION: This is the first study to compare preoperative risk stratification and PSA density as predictors of lymph node metastasis in patients who are planned for radical prostatectomy. PSA density values ≤.2 can predict lymph nodes metastasis in a larger population of patients and consequently can potentially decrease the number of lymphadenectomies during radical prostatectomy procedures.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21437595     DOI: 10.1007/s11255-011-9942-9

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  25 in total

1.  Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate.

Authors:  T A Stamey; N Yang; A R Hay; J E McNeal; F S Freiha; E Redwine
Journal:  N Engl J Med       Date:  1987-10-08       Impact factor: 91.245

Review 2.  Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience.

Authors:  M Han; A W Partin; C R Pound; J I Epstein; P C Walsh
Journal:  Urol Clin North Am       Date:  2001-08       Impact factor: 2.241

3.  Determination of prostate gland volume by transrectal ultrasound: correlation with radical prostatectomy specimens.

Authors:  J M Wolff; W Boeckmann; P Mattelaer; S Handt; G Adam; G Jakse
Journal:  Eur Urol       Date:  1995       Impact factor: 20.096

Review 4.  MR imaging and MR spectroscopy in prostate cancer management.

Authors:  Sharyn Katz; Mark Rosen
Journal:  Radiol Clin North Am       Date:  2006-09       Impact factor: 2.303

5.  Clinical use of prostate-specific antigen and prostate-specific antigen density in the staging of patients with cancer of the prostate.

Authors:  J M Wolff; W Boeckmann; P J Effert; S Handt; G Jakse
Journal:  Eur Urol       Date:  1996       Impact factor: 20.096

Review 6.  New circulating biomarkers for prostate cancer.

Authors:  K Bensalah; Y Lotan; J A Karam; S F Shariat
Journal:  Prostate Cancer Prostatic Dis       Date:  2007-11-13       Impact factor: 5.554

7.  Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005.

Authors:  Danil V Makarov; Bruce J Trock; Elizabeth B Humphreys; Leslie A Mangold; Patrick C Walsh; Jonathan I Epstein; Alan W Partin
Journal:  Urology       Date:  2007-06       Impact factor: 2.649

8.  Standard versus limited pelvic lymph node dissection for prostate cancer in patients with a predicted probability of nodal metastasis greater than 1%.

Authors:  Karim Touijer; Farhang Rabbani; Javier Romero Otero; Fernando P Secin; James A Eastham; Peter T Scardino; Bertrand Guillonneau
Journal:  J Urol       Date:  2007-05-11       Impact factor: 7.450

9.  Prostate specific antigen density: a means of distinguishing benign prostatic hypertrophy and prostate cancer.

Authors:  M C Benson; I S Whang; A Pantuck; K Ring; S A Kaplan; C A Olsson; W H Cooner
Journal:  J Urol       Date:  1992-03       Impact factor: 7.450

Review 10.  The use and accuracy of cross-sectional imaging and fine needle aspiration cytology for detection of pelvic lymph node metastases before radical prostatectomy.

Authors:  J S Wolf; M Cher; M Dall'era; J C Presti; H Hricak; P R Carroll
Journal:  J Urol       Date:  1995-03       Impact factor: 7.450

View more
  1 in total

1.  Evaluating PSA Density as a Predictor of Biochemical Failure after Radical Prostatectomy: Results of a Prospective Study after a Median Follow-Up of 36 Months.

Authors:  Stavros Sfoungaristos; Petros Perimenis
Journal:  ISRN Urol       Date:  2013-05-16
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.